Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enbridge

They already provide investors with above-average payouts today.

2 Dividend Stocks That Could Be Paying You 10% Within 5 Years

Amazon

Bristol-Myers

Hess

Microsoft

Oceaneering

Revolve

Stitch Fix

Shopify

Exxon Mobil

The Fed could begin raising rates sooner than 2023. Healthcare and utilities are climbing our sector ranking.

The Fed Has Spoken: Stocks To Buy Now

There's a lot to like with this Buffett stock.

This Is Warren Buffett's Best Dividend Stock by Far

Global Medical REIT

LTC Properties

National Health Investors

Sabra Health Care

Healthcare—along with consumer staples (“buying stuff”) and utilities (“keeping the lights on”)—provide portfolio stability.

5 Safe Healthcare Dividends Yielding 5.5%

Chevron

Verizon

These recent additions to Berkshire Hathaway's portfolio all pay at least a 4.4% yield.

Warren Buffett's Highest-Yielding Dividend Stocks

Caterpillar

CVS Health

Citizens & Northern

Discovery

General Dynamics

Kinder Morgan

Leggett & Platt

Norfolk Southern

Norwood Financial

Realty Income Corp

Healthpeak Properties

Provident Financial Services

Procter & Gamble

Starbucks

AT&T

WestRock

In May, we received $581.67 in dividend income! This was a 32.19% year over year increase compared to May 2020. Until the dividend cut is finalized, we are still receiving a boatload of dividend income from AT&T.

Dividend Income Summary: Bert's May 2021 Summary

With Humira's LOE looming in 2023, AbbVie stands to lose billions of dollars in revenues. Estimating Humira's likely losses to biosimilars in the US in 2023 and onward is more art than science, albeit there are plentiful clues to work with.

AbbVie: Beyond Humira, Framing A Bright Future

AbbVie's Humira was the world's best-selling pharmaceutical product in 2020, but is facing a loss of exclusivity and increasingly intense biosimilars competition.

AbbVie Is Going To Find It Tough Moving On From Humira

Everyone talks about how attractive ABBV is, but I couldn't find a detailed DCF model on the stock here at SA.

AbbVie Is A Bargain At The Current Price: DCF Valuation

General Motors

Merck

Sirius XM Holdings Inc

StoneCo

Suncor Energy

U.S. Bancorp

On Wednesday, we took a look at five of the 13 stocks in which Warren Buffett lightened or sold entirely Berkshire Hathaway Inc.

Warren Buffet Sold These 8 Stocks in Q1 and All Have Done Well in Q2

ABBV is a leading biotech business and on the cusp of becoming a Dividend King.

AbbVie: A Stellar Dividend Growth Pharma Stock

AbbVie has two blockbuster drugs poised to lift sales. Rinvoq's indication for atopic dermatitis is a positive catalyst. Stock offers high dividend payout and upside potential in the next few quarters.

3 Reasons AbbVie Is A Dividend Champ

DaVita

Globe Life Inc

Kroger

According to the All-in-One Screener, a Premium feature of GuruFocus, four stocks in Berkshire Hathaway Inc.'s ( BRK.A , Financial)( BRK.B , Financial) equity portfolio that have high profitability and are trading at attractive price-to-free cash flow ratios are AbbVie Inc. ( ABBV , Financial), The Kroger Co. ( KR , Financial), DaVita Inc. ( DVA , Financial) and Globe Life Inc. ( GL , Financial).

4 Warren Buffett Holdings Trading at Low Price-to-Free Cash Flow Ratios

Zhongchao

SHANGHAI, June 16, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, today announced the cooperation in physician education with AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. ("AbbVie Shanghai"), a subsidiary of AbbVie Inc (NYSE: ABBV) ("AbbVie").

Zhongchao Inc. Partners with a Subsidiary of AbbVie Inc. (NYSE: ABBV) for Medical Education Services

Johnson & Johnson

A combination of Johnson & Johnson's (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG's (OTC: RHHBY) Venclexta/Venclyxto (venetoclax) slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche's Gazyva and the chemotherapy chlorambucil in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients. The phase 3 GLOW trial data were shared at the European Hematology Association (EHA) annual meeting.

JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients

Brookfield Renewable Partners

Easterly Government Properties

Attractive yields and strong businesses make these dividend stocks great picks right now.

3 Top Dividend Stocks to Buy in June

NORTH CHICAGO, Ill., June 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® (ibrutinib) plus VENCLEXTA®/VENCLYXTO® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria.

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study

Coca-Cola

Novartis

Of the equities that make up the S&P 500, only seven have market caps larger than $200 billion and pay a dividend yield of at least 3%.

4 Buy-Rated Giants Pay a Dividend of at Least 3%

Scotts Miracle-Gro

These Stocks Could Deliver Long Term Returns For Investors The post Top Marijuana Stocks To Buy For The Long-Term? 2 Analyst Rate As A Strong Buy Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Marijuana Stocks To Buy For The Long-Term? 2 Analyst Rate As A Strong Buy Right Now

Viatris

And all three of them pay solid dividends.

3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market

NORTH CHICAGO, Ill., June 11, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a four-year follow-up analysis of the Phase 3 CLL14 trial, which showed that previously untreated patients with chronic lymphocytic leukemia (CLL) with coexisting conditions who were treated with VENCLYXTO®/VENCLEXTA® (venetoclax) plus obinutuzumab continued to show longer progression-free survival (PFS) and higher rates of undetectable minimal residual disease (MRD) compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil.

New Data Shows AbbVie's VENCLYXTO®/VENCLEXTA® Fixed Duration Combination Demonstrates Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients after Three Years off Treatment

News for AbbVie Stock (ABBV)